Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Circulation ; 115(3): 326-32, 2007 Jan 23.
Article in English | MEDLINE | ID: mdl-17210840

ABSTRACT

BACKGROUND: Cyclooxygenase (COX)-2 expression in the heart increases after myocardial infarction (MI). In murine models of MI, COX-2 inhibition preserves left ventricular dimensions and function. We studied the effect of selective COX-2 inhibition on left ventricular remodeling and function after MI in a pig model. METHODS AND RESULTS: Twenty-two pigs were assigned to COX-2 inhibition with a COX-2 inhibitor (COX-2i; celecoxib 400 mg twice daily; n=14) or a control group (n=8). MI was induced by left circumflex coronary artery ligation, and the animals were euthanized 6 weeks later. Cardiac dimensions and function were assessed with echocardiography and conductance catheters. Infarct size and collagen density were analyzed with triphenyltetrazolium chloride staining and picrosirius red staining, respectively. COX-2 inhibition increased mortality compared with controls (50% versus 0%, P=0.022), whereas infarct size was similar (13.1+/-0.7% versus 14.1+/-0.1%, P=0.536). The decrease in thickness of the infarcted myocardial wall was more pronounced in the COX-2i group (60.6+/-9.6% versus 36.2+/-5.7%, P=0.001). End-diastolic volume was higher in the COX-2i group (133.9+/-33.5 versus 91.1+/-24.0 mL; P=0.021), as was the end-systolic volume at 100 mm Hg (81.7+/-27.8 versus 56.3+/-21.1 mL; P=0.037), which indicates that systolic function was more severely impaired. Infarct collagen density was lower after COX-2i treatment (25.3+/-3.9 versus 56.1+/-23.8 gray value/mm2; P=0.005). CONCLUSIONS: In pigs, COX-2 inhibition after MI is associated with increased mortality, enhanced left ventricular remodeling, and impaired systolic function, probably due to decreased infarct collagen fiber density.


Subject(s)
Cyclooxygenase 2/metabolism , Cyclooxygenase Inhibitors/adverse effects , Myocardial Infarction/enzymology , Pyrazoles/adverse effects , Sulfonamides/adverse effects , Systole/physiology , Ventricular Remodeling/physiology , Animals , Blood Pressure/drug effects , Blood Pressure/physiology , Cardiovascular Diseases/enzymology , Cardiovascular Diseases/pathology , Celecoxib , Collagen/metabolism , Cyclooxygenase 2/drug effects , Cyclooxygenase Inhibitors/pharmacology , Disease Models, Animal , Female , Myocardial Infarction/mortality , Pyrazoles/pharmacology , Risk Factors , Sulfonamides/pharmacology , Swine , Systole/drug effects , Ventricular Remodeling/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...